Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
Protein levels in the vitreous humor may have the potential to support the diagnosis and staging of neurodegenerative diseases.
A simple blood test may help screen, identify, intervene, treat, monitor, and eventually, prevent PTSD.
The inexpensive POC device is a biosensor that performs COMT genotyping as a biomarker for hypnotizability.
A recent study provides insights on how to use automation and only 20 μL of a serum sample to quantify blood levels of antidepressants.
A new method for early detection of 14 cancer types based on glycosaminoglycan profiles shows promise.
More companies have begun offering neurofilament light chain blood tests as a cost-effective alternative to conventional methods.
A new test targeting changes in serum proteins can detect breast cancer up to two years before the condition would normally be diagnosed.
Recent study shows the new test can identify a widespread and dangerous class of synthetic cannabinoids called BZO-CHMOXIZID.
The rule would ensure Medicare coverage of newly approved breakthrough devices, but have stricter evidence standards.
Research offers new evidence that a test targeting blood-based biomarkers can predict someone’s risk of developing long COVID.